TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 150 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $64,708 | -30.0% | 7,238 | +20.3% | 0.00% | 0.0% |
| Q2 2023 | $92,406 | -16.9% | 6,016 | +21.7% | 0.00% | -25.0% |
| Q1 2023 | $111,146 | +14.1% | 4,942 | +9.8% | 0.00% | 0.0% |
| Q4 2022 | $97,447 | -11.4% | 4,501 | 0.0% | 0.00% | -20.0% |
| Q3 2022 | $110,000 | +0.9% | 4,501 | 0.0% | 0.01% | 0.0% |
| Q2 2022 | $109,000 | -6.0% | 4,501 | 0.0% | 0.01% | +25.0% |
| Q1 2022 | $116,000 | -17.1% | 4,501 | 0.0% | 0.00% | -20.0% |
| Q4 2021 | $140,000 | +28.4% | 4,501 | 0.0% | 0.01% | +25.0% |
| Q3 2021 | $109,000 | +65.2% | 4,501 | 0.0% | 0.00% | +100.0% |
| Q2 2021 | $66,000 | -41.1% | 4,501 | 0.0% | 0.00% | -50.0% |
| Q1 2021 | $112,000 | -1.8% | 4,501 | +8.0% | 0.00% | -20.0% |
| Q4 2020 | $114,000 | – | 4,169 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |